All In Biotech

Drug Trial Radar · NCT06949137

Intravenous Infusion of Human Mesenchymal Stem Cells (HMM910 ) in Postmenopausal Women With Osteoporosis at High Risk of Fracture

A Single-center, Open-label, Single-arm, 3+3 Dose-escalation Phase I Clinical Study to Evaluate Safety and Tolerability of HMM910(Human Mesenchymal Stem Cells Injection) in Postmenopausal Women With Osteoporosis and at High Risk of Fracture

Last checked: Nov 20, 2026Latest source record: Feb 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

9

Actual

Start

Jun 20, 2025

Primary completion

Mar 6, 2026

Study completion Sep 6, 2026

Sponsor

Lead sponsor
HELP Therapeutics Co., Ltd.Industry
Sponsor type
Industry
Collaborators
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
First posted
Apr 29, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 45 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to evaluate the safety and tolerability of human umbilical cord-derived mesenchymal stem cells for injection (HMM910 ) in postmenopausal women with osteoporosis who are at high risk of fracture.

Conditions

  • Osteoporosis in Post-menopausal Women
  • Osteoporosis

Interventions

  • Human Umbilical Cord-derived Mesenchymal stem cellBiological

    Intravenous infusion of human mesenchymal stem cells (HMM910 ) at 20-25 drops per minute

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and Severity of Treatment-Related Adverse EventsTime frame: Within 4 weeks after administration

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • HELP Therapeutics

    Nanjing, Jiangsu, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.